scholarly journals Antihyperglycemic and Lipid Profile Effects of Salvia amarissima Ortega on Streptozocin-Induced Type 2 Diabetic Mice

Molecules ◽  
2021 ◽  
Vol 26 (4) ◽  
pp. 947 ◽  
Author(s):  
Jesus Ivan Solares-Pascasio ◽  
Guillermo Ceballos ◽  
Fernando Calzada ◽  
Elizabeth Barbosa ◽  
Claudia Velazquez
Keyword(s):  
Lipid Profile ◽  
Oral Tolerance ◽  
Glycated Hemoglobin ◽  
Petroleum Ether Extract ◽  
Density Lipoprotein ◽  
Inhibitory Effect ◽  
Control Group ◽  
Aerial Parts ◽  
Type 2 Diabetic

Salvia amarissima Ortega was evaluated to determinate its antihyperglycemic and lipid profile properties. Petroleum ether extract of fresh aerial parts of S. amarissima (PEfAPSa) and a secondary fraction (F6Sa) were evaluated to determine their antihyperglycemic activity in streptozo-cin-induced diabetic (STID) mice, in oral tolerance tests of sucrose, starch, and glucose (OSTT, OStTT, and OGTT, respectively), in terms of glycated hemoglobin (HbA1c), triglycerides (TG), and high-density lipoprotein (HDL). In acute assays at doses of 50 mg/kg body weight (b.w.), PEfAPSa and F6Sa showed a reduction in hyperglycemia in STID mice, at the first and fifth hour after of treatment, respectively, and were comparable with acarbose. In the sub-chronic test, PEfAPSa and F6Sa showed a reduction of glycemia since the first week, and the effect was greater than that of the acarbose control group. In relation to HbA1c, the treatments prevented the increase in HbA1c. In the case of TG and HDL, PEfAPSa and F6Sa showed a reduction in TG and an HDL increase from the second week. OSTT and OStTT showed that PEfAPSa and F6Sa significantly lowered the postprandial peak at 1 h after loading but only in sucrose or starch such as acarbose. The results suggest that S. amarissima activity may be mediated by the inhibition of disaccharide hydrolysis, which may be associated with an α-glucosidase inhibitory effect.

scholarly journals Study of Correlation Between Glycated Hemoglobin (Hba1c) and Serum Lipid Profile in Type 2 Diabetic Patients

2020 ◽  
Vol 18 (1) ◽  
pp. 67-69
Author(s):  
Anil Shrestha
Keyword(s):  
Lipid Profile ◽  
Serum Lipid ◽  
Glycated Hemoglobin ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Diabetic Patients ◽  
Low Density ◽  
Type 2 Diabetic Patients ◽  
Type 2 Diabetic

Introduction: Diabetic mellitus is a chronic metabolic disease characterized by hyperglycemia. Type 2 diabetes mellitus accounts for more than 90% of cases worldwide. Elevated HbA1c and dyslipidemia proportionately increases the risk of development of cardiovascular disease (CVD) which is the major cause of morbidity and mortality worldwide. Aims: To Study the correlation between glycated hemoglobin (HbA1c) and serum lipid profile in type 2 diabetic patients. Methods: This is a hospital based cross sectional study conducted at Nepalgunj medical college teaching hospital, which included 104 type 2 diabetic patients (54 males and 50 females).Venous blood samples were collected from all patients and serum was used for analyzing HbA1c, lipid profile panel and fasting blood glucose (FBG). DM was defined as per American diabetic association (ADA) criteria. Dyslipidemia was defined as per the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Guidelines. The data were analyzed using standard statistical methods, including SPSS 21. Results : Abnormal lipid parameters were demonstrated with increased Total Chloseterol (TC), Triglyceride (TG), Low density lipoprotein (LDL),Very low density lipoprotein (VLDL) and low High density lipoprotein (HDL)  suggestive of dyslipidemia.HbA1c showed direct and significant correlation with TC,LDL,TG and VLDL. Patients with HbA1c  > 7.0% had a significantly higher value of TC, LDL, TG and VLDL as compared to patients with HbA1c ≤7.0%.However, the significant difference in value of HDL-C was not found between two groups. Conclusion: Due to the strong correlation with lipid profile, HbA1c could be the ideal marker for predicting dyslipidemia in type 2 DM . Patients with higher HbA1c value and dyslipidemia should be considered as a very high risk group for CVD.

scholarly journals Effect of atorvastatin on oxidative stress parameters and lipid profile in type 2 diabetic patients

2020 ◽  
Vol 7 (2) ◽  
Author(s):  
Najah RH ◽  
Mohammad AAH ◽  
Ammar RMR
Keyword(s):  
Oxidative Stress ◽  
Lipid Profile ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Oxidative Stress Parameters ◽  
Type 2 Diabetic ◽  
Stress Parameters

Introduction: Evidence has long existed regarding the relationship between oxidative stress and diabetes. The present study was conducted to assess the effect of atorvastatin on selected oxidative stress parameters in the form of reduced glutathione (GSH), lipid peroxidation byproduct malondialdehyde (MDA) levels, glutathione –S- transferase (GST) activity and catalase (CAT) activity) and its effect on lipid profile (total cholesterol (TC), triglyceride (TG), high density lipoprotein (HDL), low density lipoprotein (LDL) and very low density lipoprotein (VLDL) in dyslipidaemic type 2 diabetic patients . Materials and Methods: Fifty nine dyslipidaemic type 2 diabetic patients were included in this study. Full history was taken and general examination of patients was performed. Patients studied were taking glibenclamide (an oral hypoglycaemic drug) during the study as a treatment for their disease. These patients were followed up for 60 days and divided randomly into 2 groups. Group I (n = 31): no drug was given and served as dyslipidaemic diabetic control. Group II (n = 28): received atorvastatin tablets 20 mg once daily at night. Of the 59 Fifty patients, 46 completed the study while 13 patients withdrew. This is due to non compliance of the patients. Blood samples were drawn from the patients at the beginning and after 60 days of follow up between 8:30 & 10:30 am after at least 12-14 hours fast. Fasting blood glucose, lipid profile, selected oxidative stress parameters (GSH, MDA levels, GST and CAT activities) were measured. Renal and hepatic functions were also assessed. Results: This study revealed that: atorvastatin treatment increased serum GSH; reduced MDA levels significantly while did not significantly affect CAT and GST activity. In atorvastatin treatment, TC, TG, LDL and VLDL decreased significantly while HDL increased significantly. Conclusion: There was insignificant correlations between atorvastatin induced changes in the oxidation markers and the observed changes of the lipid profile.

scholarly journals A controlled study of consumption of β-glucan-enriched soups for 2 months by type 2 diabetic free-living subjects

2009 ◽  
Vol 103 (3) ◽  
pp. 422-428 ◽  
Author(s):  
Christine Cugnet-Anceau ◽  
Julie-Anne Nazare ◽  
Maria Biorklund ◽  
Elodie Le Coquil ◽  
Agnès Sassolas ◽  
...  
Keyword(s):  
Lipid Profile ◽  
Glucose Control ◽  
Dietary Intervention ◽  
Fasting Glucose ◽  
Controlled Study ◽  
Control Group ◽  
Free Living ◽  
Apo B ◽  
Type 2 Diabetic

Type 2 diabetes is associated with a higher cardiovascular risk and there has been a growing interest in using dietary intervention to improve lipid profile and glucose control. The present work aims at analysing the effects of the enrichment of a normal diet with β-glucan (3·5 g/d) in free-living type 2 diabetic subjects for 2 months, using a palatable soup. This trial was a parallel, placebo-controlled, double-blinded randomised study performed in fifty-three type 2 diabetic subjects. During a 3-week run-in period, subjects daily consumed a ready meal control soup (without β-glucan). For the following 8 weeks, subjects were randomly assigned to consume daily either a control soup or a β-glucan soup. Changes in lipid profile (total cholesterol (TC), HDL- and LDL-cholesterol (HDLc and LDLc), apo B and TAG) and in glucose control (HbA1c and fasting glucose) were measured. There was no significant alteration in lipid profile in the two groups (TC, HDLc, LDLc and apo B). TAG decreased significantly in the β-glucan group compared with the control group ( − 0·12 (sd0·38)v. 0·12 (sd0·44) mmol/l,P = 0·03). HbA1c and fasting glucose were not reduced in any group. A single daily ingestion of 3·5 g β-glucan, as required by official dietary recommendations, for 8 weeks did not change the lipid profile and HbA1c in type 2 diabetic subjects. To improve the metabolic profile of type 2 diabetic subjects in the long term, the quantity, the food vectors and the tolerability of β-glucan products may be re-evaluated.

scholarly journals Glycated haemoglobin acts as an indicator of dislipidemia in patients with Type II diabetes mellitus

2018 ◽  
Vol 5 (2) ◽  
pp. 185-192
Author(s):  
Sumaia Sahrin ◽  
Dilruba Easmin Jharna ◽  
M Shafiqul Islam Khan ◽  
Jayati Debnath ◽  
Suman Talukder
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Glycemic Control ◽  
Lipid Profile ◽  
Serum Lipid ◽  
Glycated Hemoglobin ◽  
Density Lipoprotein ◽  
Good Glycemic Control

Diabetic patients with associated dyslipidemia are easy targets for cardiovascular diseases (CVD). Glycated hemoglobin predicts the risk for the development of diabetic complications. This study was an attempt to determine lipid abnormalities associated with Type-2 Diabetes Mellitus and association between glycated hemoglobin (HbA1c) levels and serum lipid profile to assess the importance of HbA1c as an indicator of dyslipidemia and future risk of cardiovascular disease in Bhola District, Barisal. In this cross-sectional study, 200 known patients of Type-2 Diabetes Mellitus within 35-85 years of age were randomly selected. They were investigated for HbA1c and lipid profile. The data were evaluated by Statistical Package for Social Sciences (SPSS) 16.0 version software. Independent samples t-test (2-tailed) was used to compare means of anthropometric, clinical and laboratory parameters and the effect of the glycemic control on their lipid profile was determined using correlation coefficient. Amongst the study group, 65% patients showed poor glycemic control, 35% with good glycemic control and 59.60% patient’s haddyslipidemia.HbA1c was found to have significant positive correlation with total cholesterol (TCHO), low density lipoprotein (LDL-C) and triglycerides (TG) and significant negative correlation with high density lipoprotein (HDL-C). The mean value of TC, LDL-C and TG was found to be lower in patients with good glycemic control than those with poor glycemic control. These differences were significant at the level of P<0.05. These findings conclude that the glycemic control of the patient has got a strong impact on the serum lipid level and dyslipidemia is frequently encountered in those who have got poor glycemic control.Res. Agric., Livest. Fish.5(2): 185-192, August 2018

scholarly journals The role of glycated hemoglobin (HbA1c) and serum lipid profile measurements to detect cardiovascular diseases in type 2 diabetic patients

2016 ◽  
Vol 5 (2) ◽  
pp. 30-34 ◽  
Author(s):  
Muhammad Naeem ◽  
Rehman Mehmood Khattak ◽  
Mati Ur Rehman ◽  
Muhammad Nasir Khan Khattak
Keyword(s):  
Blood Pressure ◽  
Cardiovascular Diseases ◽  
Lipid Profile ◽  
Serum Lipid ◽  
Glycated Hemoglobin ◽  
Density Lipoprotein ◽  
Serum Lipid Profile ◽  
Diabetic Patients

Patients with diabetes are considered to be at more risk of dyslipidemia and hypertension, hence targets for cardiovascular diseases. This study describes the possible role of Glycated Hemoglobin (HbA1c) and serum lipid profile as a biomarker in the detection of cardiovascular diseases. A cross-sectional study was carried out on 54 (33 males and 21 females) type 2 diabetes (T2DM) patients at Ayub Teaching Hospital (ATH), Abbottabad and Mardan Medical Complex (MMC), Mardan, Khyber Pukhtunkhwa (KP), Pakistan. The control group comprised of 20 (13 males and 7 females) healthy human samples. The patients had significantly higher (p<0.05) Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP), HbA1c, Fasting Blood Glucose (FBG), Total Cholesterol (TC), Triglyceride (TG) compared to control subjects. Only High Density Lipoprotein (HDL) was found to be significantly (p<0.05) lower in the patients compared to controls. With regards to gender, in the female patients SBP, DBP, TC and Low Density Lipoprotein (LDL) were significantly higher (p<0.05) compared to males patients. The HbA1c was found to be significantly higher (p<0.05) in males. Results also revealed that patients having HbA1c>7.0%, had higher TG than those with HbA1c?7.0%. Furthermore, 14.2% patients with HbA1c>7.0% had cerebrovascular diseases and 28% have ischemic heart diseases. The findings of the current study suggests association of HbA1c with lipid profile in T2DM patients and both might be used as a predictor of cardiovascular diseases in such patients.South East Asia Journal of Public Health Vol.5(2) 2015: 30-34

scholarly journals Effect of atorvastatin and metformin combination therapy in type 2 diabetic dyslipidemias

2020 ◽  
Vol 9 (7) ◽  
pp. 1069
Author(s):  
Ramsha Saman ◽  
Margaret Voila
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Fatty Acids ◽  
Type 2 Diabetes Mellitus ◽  
Combination Therapy ◽  
Free Fatty Acids ◽  
Lipid Profile ◽  
Density Lipoprotein ◽  
Type 2 Diabetic

Background: Dyslipidaemia is a major risk factor for cardiovascular complications in patients with type 2 diabetes mellitus and affects 10-73% of this population. In type 2 diabetes mellitus, increased efflux of free fatty acids from adipose tissue and impaired insulin mediated skeletal muscle uptake of free fatty acids, increases fatty acid flux to the liver and also decreased glucose utilization in muscle that leads to acute elevation of free fatty acids. Lipid profile which is altered in diabetes state is one of the significant factors in development of cardiovascular diseases. The derangements seen in serum lipid profile includes: increased total cholesterol (TC), triglycerides (TG) and low-density lipoprotein (LDL) and decreased high-density lipoprotein cholesterol (HDL) concentration. Hence with the aforementioned views the present study had been planned to evaluate the effect of atorvastatin and metformin combination therapy in type 2 diabetic dyslipidemias.Methods: Study design, observational prospective study, with duration of 4-5 months and sample size of 30 patients with type 2 diabetes mellitus are taken with mild to moderate dyslipidemias. The study subjects received combination therapy of metformin 500 mg/day along with atorvastatin 20mg/day, there effect is seen on serum lipid profile and fasting blood glucose levels (FBS).Results: There was a significant mean decrease in TC, LDL , TG , FBS by 31.7 mg/dl (p<0.05), 28.5 mg/dl (p value <0.05), 19.5 mg/dl (p<0.05), 9.13 mg/dl (p<0.05) respectively and rise in HDL by 1.7 mg/dl (p<0.05) ), no significant decrease in VLDL (p>0.05).Conclusions: Combination of atorvastatin and metformin was effective in reduction of TC, LDL, TG and FBS and elevation of HDL levels in type-2 diabetic dyslipidemias.

scholarly journals Effect of hypothyroidism on lipid profile of type 2 diabetic patients

2020 ◽  
Vol 7 (5) ◽  
pp. 754
Author(s):  
Damanpreet Singh ◽  
Gurinder Mohan ◽  
Arshdeep Bansal
Keyword(s):  
Type 2 Diabetes ◽  
Lipid Profile ◽  
Diabetic Complication ◽  
Control Group ◽  
P Value ◽  
Diabetic Patients ◽  
Study Group ◽  
Type 2 Diabetic Patients ◽  
Type 2 Diabetic

Background: Hypothyroidism is an endocrine disorder resulting from deficiency of thyroid hormones, and Diabetes is a metabolic disorder that share the phenotype of hyperglycaemia. Both the endocrinopathies have been found to be associated with dyslipidaemia and atherosclerosis that result into various complications. Our aim was to assess the difference of dyslipidaemia in patients suffering from hypothyroidism with diabetes as compared to diabetes alone.Methods: Study was conducted in department of medicine in SGRDIMSR, Sri Amritsar. A total of 120 patients were enrolled for the present study, the one who presented to hospital from January 2018 to August 2019 diagnosed with diabetes mellitus type 2. The patients were divided into two groups. 60 patients having type 2 diabetes without hypothyroidism (control group). 60 patients having type 2 diabetes with hypothyroidism (study group). Fasting lipid profile were performed in both the groups and were analysed for the study.Results: Dyslipidaemia was seen more in study group as compared to control group with mean cholesterol of 488.3(±144.43) and mean triglyceride levels of 354.30(±128.57) in study  group as compared to control group with mean cholesterol and triglyceride levels of 179.7(±81.47) and 177.08(±118.18) with p-value of 0.001 and 0.01 respectively which were significant. Also, obesity and diabetic complication were more in patients of dual endocrinopathies as compared to diabetes alone which were also significant statistically.Conclusions: From our study it is concluded that type 2 diabetes with hypothyroidism causes more dyslipidaemia as compare to type 2 diabetes alone. So proper screening of thyroid profile of type 2 diabetic patients and its correction helps in achieving better lipidemic control which further prevent complications.

scholarly journals Serum Lipids and Diabetic Retinopathy in Newly Diagnosed Type 2 Diabetic Subjects

2012 ◽  
Vol 1 (2) ◽  
pp. 63-66
Author(s):  
Md Rezwanur Rahman ◽  
M Iqbal Arslan ◽  
Md Mozammel Hoque ◽  
Forhadul Hoque Mollah ◽  
Shahana Shermin
Keyword(s):  
Diabetic Retinopathy ◽  
Lipid Profile ◽  
Density Lipoprotein ◽  
Serum Triglyceride ◽  
Vascular Complication ◽  
Lipoprotein Cholesterol ◽  
Newly Diagnosed ◽  
Significant Difference ◽  
Type 2 Diabetic

Background: Diabetic retinopathy is the commonest and usually the first observable vascular complication of diabetes mellitus. Along with hyperglycaemia, dyslipidaemia is a contributing factor for the occurrence of diabetic retinopathy. It is postulated that dyslipidaemia results in formation of hard exudate by increasing blood viscosity and altering the fibrinolytic system. A case control study was carried out in the department of Biochemistry, Bangabandhu Sheikh Mujib Medical University, Dhaka during the period of January 2006 to December 2007 to evaluate the serum lipid profile in newly diagnosed type 2 diabetic subjects with diabetic retinopathy.Materials and Methods: Total 85 newly diagnosed type 2 diabetic subjects were included in this study, 40 were cases having retinopathy and 45 were age and sex matched controls without retinopathy. Serum triglyceride (TG), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C) and high density lipoprotein cholesterol (HDL-C) were compared between cases and controls. Unpaired t-test and chi-square test were done between groups as tests of significance.Results: All the parameters of lipid profile showed dyslipidaemic trend both in cases and controls. In the cases TG was significantly higher and HDL-C was significantly lower than that of controls (p < 0.05) whereas no significant difference was found between cases and controls with respect to serum TC and LDL-C.Conclusion: It can be concluded that high TG and low HDL-C are associated with diabetic retinopathy in newly diagnosed type 2 diabetes. DOI: http://dx.doi.org/10.3329/jemc.v1i2.11464 J Enam Med Col 2011; 1(2): 63-66

scholarly journals Relation between Serum Leptin, Lipid Profiles and other biomarkers levels in patients with type 2 diabetic nephropathy

2010 ◽  
Vol 7 (1) ◽  
pp. 678-686
Author(s):  
Baghdad Science Journal
Keyword(s):  
Diabetic Nephropathy ◽  
Serum Creatinine ◽  
Lipid Profile ◽  
Plasma Glucose ◽  
Fasting Plasma Glucose ◽  
Control Group ◽  
Diabetic Patients ◽  
Serum Leptin ◽  
Type 2 Diabetic

Background: In advanced diabetes mellitus, serum levels of the most hormones are altered due to several interplaying mechanisms. Objective: To assess the relation of serum leptin and lipid profile in type 2 diabetic nephropathy. Patients and Method: Serum leptin levels and its relation to lipid profile were estimated in 62 patients with type 2 diabetic nephropathy attending the National Diabetes Center in Al- Mustansiriya University, and (26) healthy individuals considered as control group. The diabetic patients were classified into three groups, (24) pathients with normoalbuminuria (21) patients with microalbuminuria and (17) patients with macroalbuminuria. Fasting plasma glucose, serum creatinine, Hb A1c %, lipid profile (Total cholesterol, LDL- Cholesterol, HDL- Cholesterol and Triglyceride) and urinary albumin, were measured to establish the possibility of using these biomarkers as a supplementary to serum leptin to be a diagnostic test for type 2 diabetic nephropathy. Results: Serum leptin levels showed a significant elevation in microalbuminuria (20.08± 4.50 ng/ml) and macroalbuminuria groups (22.35± 6.89 ng/ml) as compared to nondiabetic normal control group (10.64 ± 3.17 ng/ml). There was no significant differences observed in serum leptin levels between the normoalbuminuria group (13.96 ± 5.73 ng/ml) and healthy controls, but a significant positive differences were noticed in the levels of fasting plasma glucose, serum creatinine, Hb A1c% and lipid profile in the three patient groups in comparison with the control group. While no significant correlation was observed between these biomarkers levels and serum leptin values. Conclusion: It might be concluded that serum leptin levels were elevated in type 2 diabetic patients with microalbuminuria and macroalbuminuria, suggesting that renal leptin degradation is impaired in early stage of kidney damage and this impairment increase with the progression of this disease. Leptin hormone may consider according to these results as a risk factor for progression of kidney disease in diabetic patients.

Sign in / Sign up

Export Citation Format

Share Document